TÜBINGEN, Germany / BOSTON, USA – August 18, 2020

CureVac N.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its initial public offering of 15,333,332 common shares, which includes the full exercise by the underwriters of their option to purchase 1,999,999 common shares, at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $245.3 million. Concurrent with the initial public offering, Mr. Dietmar Hopp, co-founder of SAP and dievini Hopp BioTech, the company’s majority shareholder, through DH-LT-Investments GmbH and affiliated entities, purchased in a private placement €100 million of common shares at the initial public offering price. The common shares began trading on The Nasdaq Global Market on August 14, 2020 under the ticker symbol “CVAC.”

BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the offering, with Berenberg and Kempen & Co acting as passive book-running managers.

Dr. Franz-Werner Haas, Chief Executive Officer of CureVac, said: “An initial public offering is a special milestone in every company’s history; and it is the culmination of months of hard work by the entire CureVac team. We continue to focus on the development and manufacturing of mRNA-based vaccines against Covid-19 and other infectious diseases, as well as product candidates in the field of oncology and protein therapy.”

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on August 13, 2020. The offering was made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained for free by visiting EDGAR on the Securities and Exchange Commission’s (“SEC”) website at www.sec.gov. Alternatively, a copy of the final prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, by telephone at (800) 299-1322 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About CureVac

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of rare diseases. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.


CureVac-QueriesMedia Queries

Thorsten Schüller
Corporate Communications

CureVac, Tübingen, Germany
T +49 7071 9883-1577

Email

CureVac-QueriesInvestor Queries

Dr. Sarah Fakih
Vice President Investor Relations

CureVac, Tübingen, Germany
T +49 7071 9883-1298
M +49 160 – 90496949

Email

Download PDF


Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections CureVac regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.  Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur.  The forward-looking statements included in this press release are made only as of the date hereof. The company  does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CureVac N.V.
Tübingen, GermanyFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac AG
Tübingen, GermanyHeadquartersFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac AG
Frankfurt, GermanyClinical developmentSchumannstr. 2760325 FrankfurtT +49 69 7680 587 - 0F +49 69 7680 587 - 2222
CureVac Manufacturing GmbH
Tübingen, GermanyFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Corporate Services GmbH
Tübingen, GermanyFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Inc.
Boston, USA250 Summer St 3rd FlBoston, MA 02210, USAP +1 617 377404 - 0
CureVac Swiss AG
Basel, SwitzerlandWartenbergstraße 40CH-4052 BaselT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac RNA Printer GmbH
Tübingen, GermanyFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Belgium SA
Ottignies-Louvain-la-Neuve, BelgiumAv. Jean Monnet 41348 Ottignies-Louvain-la-Neuve
CureVac Netherlands. B.V.
Amsterdam, the NetherlandsScience Park 1061098 XG AmsterdamT +31 20 237 4970
Social